In a number of experimental models of CNS disorders, xCT inhibition, using either genetic or pharmacological approaches, has been found to be more often neuroprotective than deleterious e.g. in 6OHDA-induced Parkinson’s disease12 and middle cerebral artery occlusion15. The gene discussed is SLC7A11; the disease is central nervous system disorder.